8-K: Spruce Biosciences Shifts Focus to Sanfilippo Syndrome Type B with Acquisition of Tralesinidase Alfa

Spruce Biosciences announces a new corporate strategy centered around the acquisition of Tralesinidase Alfa (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB), with a BLA submission anticipated in the first half of 2026.

Summary

• Spruce Biosciences is shifting its focus to neurological disorders with the acquisition of Tralesinidase Alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB).
• The company plans to submit a Biologics License Application (BLA) to the FDA for TA-ERT in the first half of 2026.
• TA-ERT has shown to normalize cerebral spinal fluid (CSF) heparan sulfate non-reducing end (HS-NRE) levels over a five-year period in clinical studies.
• The FDA has indicated that HS-NRE could be used as a biomarker to predict clinical benefit and serve as a basis for accelerated approval.
• Spruce intends to seek accelerated approval of TA-ERT for MPS IIIB based on existing non-clinical and clinical data and will initiate a confirmatory trial as a condition of approval.
• The company plans to build a specialized commercial and medical affairs organization to support the commercialization of TA-ERT in the U.S.
• Spruce also intends to commercialize TA-ERT globally, establishing its own commercial organization in the U.S., EU, and the UK, and seeking strategic collaborations in other international markets.
• As of December 31, 2024, Spruce had $38.8 million in cash and cash equivalents, which is expected to fund its operating plan through the end of 2025.
• There are 42.2 million shares of common stock issued and outstanding and 21.4 million shares of common stock reserved for issuance of warrants and equity securities as of December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strategic acquisition, clear regulatory pathway, and potential for accelerated approval. However, the need for a confirmatory trial and limited cash runway introduce some uncertainty.

Positives

• TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by MPS IIIB, as there are currently no FDA-approved treatments available.
• The FDA has confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval.
• TA-ERT has received fast-track designation, rare pediatric disease designation, and orphan drug designation in the U.S. and EU.
• Spruce has alignment with the FDA on key design elements of a confirmatory trial, which can be initiated prior to potential accelerated approval of TA-ERT.
• The company believes that developing drugs that directly impact known disease pathways will increase the probability of success of its development programs.

Negatives

• Spruce will need to initiate a confirmatory trial as a condition of seeking accelerated approval of a BLA from the FDA.
• The company expects its cash runway to fund its current operating plan only through the end of 2025, suggesting a potential need for future financing.
• The success of the new corporate strategy is dependent on the regulatory approval and commercialization of TA-ERT.

Risks

• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• Risks and uncertainties include those associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the SEC.
• The company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time.
• The company's ability to obtain and maintain regulatory approval of its product candidates is subject to risks.
• The company's ability to commercialize its product candidates is subject to risks.

Future Outlook

Spruce anticipates submitting a BLA for TA-ERT to the FDA in the first half of 2026 and seeks accelerated approval of TA-ERT for MPS IIIB based on existing non-clinical and clinical data. The company expects its cash runway to fund its current operating plan through the end of 2025.

Management Comments

• 'This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-term commercial opportunity with TA-ERT in MPS IIIB,' said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce.
• 'The vision of the Spruce leadership team and their unrelenting commitment to serving patient communities with meaningful unmet need is on full display with the acquisition of TA-ERT,' said Mike Grey, Executive Chairman of Spruce.

Industry Context

The acquisition of TA-ERT positions Spruce Biosciences in the enzyme replacement therapy market for MPS disorders, a space with existing players like BioMarin and Ultragenyx. The focus on a specific subtype, MPS IIIB, allows Spruce to target a niche market with significant unmet need.

Comparison to Industry Standards

• BioMarin's Vimizim for MPS IVA generated $740M in 2024 annual worldwide net sales, showcasing the potential of enzyme replacement therapies in MPS disorders.
• Ultragenyx's Mepsevii for MPS VII generated $30M in 2024 annual worldwide net sales.
• Other MPS therapies like Aldurazyme and Elaprase have also achieved significant sales, indicating a robust market for these treatments.
• The consistent year-over-year growth trajectories of MPS therapies highlight that earlier diagnosis and improved awareness contribute to strong market uptake.

Stakeholder Impact

• Shareholders: The new corporate strategy and acquisition of TA-ERT could potentially increase shareholder value if the drug is approved and successfully commercialized.
• Patients and Families: TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by MPS IIIB, as there are currently no FDA-approved treatments available.
• Employees: The company plans to build a specialized commercial and medical affairs organization, which could create new job opportunities.

Next Steps

• Submit a Biologics License Application (BLA) to the FDA for TA-ERT in the first half of 2026.
• Initiate a confirmatory trial for TA-ERT.
• Build a specialized commercial and medical affairs organization to support the commercialization of TA-ERT in the U.S.
• Seek regional strategic collaborations and a network of third-party distributors in other international markets.

Key Dates

Keywords

Tralesinidase Alfa, Sanfilippo Syndrome Type B, MPS IIIB, Enzyme Replacement Therapy, BLA Submission, Accelerated Approval, HS-NRE, Spruce Biosciences, Rare Disease, Neurological Disorders